Stephanie Shearer, DO
Family Medicine · Lansdale, PANPI 1558469080
Payments from drug & device makers
Across 297 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$920
- Novo Nordisk$671
- Merck$367
- Lilly USA, LLC$355
- Pfizer$312
- Boehringer Ingelheim$279
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,137100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $920 |
| Novo Nordisk | 32 | $671 |
| Merck | 26 | $367 |
| Lilly USA, LLC | 19 | $355 |
| Pfizer | 19 | $312 |
| Boehringer Ingelheim | 13 | $279 |
| AstraZeneca | 18 | $274 |
| Amgen | 18 | $272 |
| Daiichi Sankyo Inc. | 9 | $155 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $133 |
| Novartis | 7 | $123 |
| Abbott | 6 | $105 |
| Bayer | 5 | $102 |
| Johnson & Johnson | 7 | $102 |
| GSK | 5 | $91 |
| Sanofi-aventis U.S. LLC | 3 | $82 |
| Teva Pharmaceuticals USA, Inc. | 5 | $74 |
| Alk-abello, Inc | 4 | $74 |
| Biohaven Pharmaceuticals, Inc. | 4 | $71 |
| Sunovion Pharmaceuticals Inc. | 5 | $65 |
| Astellas Pharma US Inc | 4 | $62 |
| Eisai Inc. | 4 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| Amarin Pharma, Inc. | 4 | $54 |
| Sanofi Pasteur Inc. | 2 | $46 |
| Sun Pharmaceutical Industries Inc. | 2 | $45 |
| Almatica Pharma LLC | 2 | $42 |
| Biofire Diagnostics, LLC | 1 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Radius Health, Inc. | 2 | $28 |
| Grifols USA, LLC | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Optinose US, Inc. | 1 | $11 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$119
How this compares
$5,137 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 114 | $113,713 |
| JardianceEmpagliflozin | 92 | $107,410 |
| EliquisApixaban | 78 | $84,468 |
| TrulicityDulaglutide | 54 | $69,210 |
| JanuviaSitagliptin Phosphate | 45 | $39,559 |
| OzempicSemaglutide | 29 | $34,032 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $30,605 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $25,345 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $23,968 |
| XareltoRivaroxaban | 16 | $22,342 |
| AtivanLorazepam | 11 | $21,637 |
| MounjaroTirzepatide | 17 | $18,637 |
| Repatha SureclickEvolocumab | 20 | $17,310 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $14,369 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $11,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $274 | $113,713114 claims |
| Boehringer IngelheimJardiance | $279 | $107,41092 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $355 | $87,84771 claims |
| PfizerEliquis | $312 | $84,46878 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $91 | $42,15076 claims |
| MerckJanuvia | $367 | $39,55945 claims |
| Novo NordiskOzempic | $671 | $34,03229 claims |
| Johnson & JohnsonXarelto | $102 | $22,34216 claims |
| AbbVieLinzess, Synthroid | $920 | $8,37160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Lansdale
- Robert DetweilerLansdale$684K
- Evan KesslerLansdale$231K
- Michael ParkeLansdale$119K
- Jack RosenfeldLansdale$95K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.